A, ROS production measured using 2′,7′-dichlorofluorescein (DCF) fluorescence with and without CCA and treated with vehicle, RSV, or quercetin using the 4-day protocol. Con, control. B, COX-IV protein expression in vehicle and RSV-treated C2C12 myotubes, with or without CCA, using the 4-day protocol is shown graphically. C, COX activity in vehicle, RSV, quercetin- or NAM-treated myotubes, with or without the 4-day protocol of CCA. D, mitochondrial mass measured using MTGFM in a 6-well cell culture plate. E, MTGFM-stained C2C12 myotubes that were treated with CCA, vehicle, or RSV using the 4-day protocol. Images were taken using a fluorescent microscope (n = 9–12, arbitrary scanner units (A.U.) corrected for loading using GAPDH; *, p < 0.05, overall effect of CCA; ‡, p < 0.05, overall effect of treatment versus vehicle-treated control; †, p < 0.05, interaction of treatment versus vehicle-treated myotubes; ϵ, p < 0.05, versus myotubes treated with CCA/RSV).